X-Cell Medical's mission is to discover and develop alternative drugs for device-drug combinations, believing that the drug in such combination products is the most valuable component. The company has in-house expertise in drug discovery, formulation, and polymer coatings, as well as a deep set of cardiovascular device experience, coming from its medical advisory board, which consists of some of the most influential cardiology device users in the world.
11 Deer Park Drive, Suite 208
Monmouth Junction, NJ 08852
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.
The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.
A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.
The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.